Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations. The requesting Treating Physician submitted a request for access to drug (often referred to as Compassionate Use) to Novartis which was reviewed and approved by the medical team experienced with the drug and indication. This program will provide access to patients until: * All participating countries have received marketing authorization and product is commercially available and accessible to all participating patient(s) or * Alternative treatment options are available and/or * In case of changes in the safety profile or a lack of overall efficacy of the product.